# A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

> **NCT07387367** · PHASE3 · RECRUITING · sponsor: **SymBio Pharmaceuticals** · enrollment: 180 (estimated)

## Conditions studied

- Adenovirus Infections

## Interventions

- **DRUG:** cidofovir
- **DRUG:** Brincidofovir

## Key facts

- **NCT ID:** NCT07387367
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07387367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07387367, "A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07387367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*